Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery

Ching-Li Tseng, Yueh Hsiu Wu, Su Wen Yu, Kai-Chiang Yang, Feng Huei Lin

研究成果: 書貢獻/報告類型會議貢獻

2 引文 斯高帕斯(Scopus)

摘要

Lung cancer is a harmful form of cancer. The long-term survival rate of lung cancer patients treated by conventional modalities remains far from satisfactory. Encapsulated anticancer drugs in nanocarriers, can protect not only the integrity of drugs during transport but also the normal tissues from the toxicity. To develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidin FITC-biotinylated epidermal growth factor (bEGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Cisplatin, a key drug used in the chemotherapy with sever side effect, was incorporated in the nanocarriers for active targeting to reduce toxicity. Furthermore, these nanocarriers were given to mice via inhalation of aerosol droplets which were generated by a nebulizer and delivered to mice model of lung cancer via aerosol. To summarize, the in vivo targeting ability of GP-Av-bEGF was examined by fluorescence images obtained from live mice showed that these nanoparticles could target the cancerous lungs in a more specific manner by aerosol delivery. And gelatin nanoparticles loaded with cisplatin and decorated with EGF tumor-specific ligand (GP-PtbEGF) were also successfully developed. Their in vitro and in vivo targeting ability and anticancer effect were confirmed. This treatment showed that GP-Pt-bEGF had stronger antitumor activity and was less toxic compared with other cisplatin formulas. Furthermore, these formulations were given to mice with lung cancer via aerosol delivery and showed that inhaled GP-Pt-bEGF could target EGFR-overexpressing cells to achieve high cisplatin dosage in cancerous lungs. The aerosol delivery of nanocarriers was demonstrated here. Simple aerosol delivery of targeted drug carriers may prove useful for the clinical treatment of lung cancer patients to eliminate patient complaints associated with the frequent intravenous injection.
原文英語
主出版物標題World Congress on Medical Physics and Biomedical Engineering
主出版物子標題Micro- and Nanosystems in Medicine, Active Implants, Biosensors
發行者Springer Verlag
頁面347-350
頁數4
版本8
ISBN(列印)9783642038860
DOIs
出版狀態已發佈 - 2009
對外發佈
事件World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors - Munich, 德國
持續時間: 9月 7 20099月 12 2009

出版系列

名字IFMBE Proceedings
號碼8
25
ISSN(列印)1680-0737

其他

其他World Congress on Medical Physics and Biomedical Engineering: Micro- and Nanosystems in Medicine, Active Implants, Biosensors
國家/地區德國
城市Munich
期間9/7/099/12/09

ASJC Scopus subject areas

  • 生物工程
  • 生物醫學工程

指紋

深入研究「Development of EGFR-targeting nanomedicine for effectively and noninvasively treats lung cancer patients by aerosol delivery」主題。共同形成了獨特的指紋。

引用此